CENTRAL TRUST Co Acquires 1,880 Shares of Cencora, Inc. $COR

CENTRAL TRUST Co boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 116.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,500 shares of the company’s stock after buying an additional 1,880 shares during the quarter. CENTRAL TRUST Co’s holdings in Cencora were worth $1,094,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in COR. Vanguard Group Inc. increased its stake in shares of Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after purchasing an additional 1,125,661 shares during the last quarter. Geode Capital Management LLC grew its holdings in Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after purchasing an additional 284,229 shares during the period. Norges Bank bought a new position in Cencora during the second quarter valued at $695,215,000. Viking Global Investors LP increased its position in Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Finally, Amundi raised its stake in shares of Cencora by 17.0% in the second quarter. Amundi now owns 1,720,278 shares of the company’s stock valued at $500,893,000 after buying an additional 249,742 shares during the period. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on COR shares. Evercore cut their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Wells Fargo & Company lifted their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday. TD Cowen upped their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Barclays raised their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Cencora Trading Up 2.7%

Shares of Cencora stock opened at $360.59 on Friday. The company’s 50-day moving average price is $347.51 and its 200-day moving average price is $328.62. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12-month low of $237.71 and a 12-month high of $377.54. The company has a market cap of $69.95 billion, a price-to-earnings ratio of 43.34, a PEG ratio of 1.66 and a beta of 0.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same quarter in the prior year, the firm posted $3.73 EPS. Cencora’s revenue was up 5.5% on a year-over-year basis. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,316 shares of company stock valued at $7,151,265 in the last 90 days. Corporate insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.